OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

The combined company will operate under the Nova Biomedical name offering analytical instruments, reagents, and services.

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

Humanetics Corporation, a clinical-stage pharmaceutical company, has selected Lifecore Biomedical, a fully integrated CDMO, ...

Araris is advancing three preclinical candidates for the treatment of hematological and solid tumors developed using its ...

He previously led regulatory groups in the UK and Europe, overseeing the development and execution of global client solutions ...

In today’s continuously evolving pharmaceutical landscape, patient-centricity is more than just a buzzword—it’s a critical component of drug delivery and packaging innovation. As pharmaceutical ...

Delpharm, a CDMO, has reached an agreement with the Government of Canada to modernize its injectable manufacturing facility in Boucherville.

Kincell Bio, a cell therapy developer and manufacturer, has appointed Larry Pitcher as Chief Operating Officer (COO).

Huyabio International has appointed Paul Spreen as Chief Business Officer. “We are delighted to welcome Paul Spreen to the HUYA executive team,” said Dr. Mireille Gillings, President, CEO & Executive ...

The combination of Mallinckrodt and Endo will create a strong pharmaceutical company with a diversified portfolio, enhanced ...

Achieves ISO9001, EFfCI GMP, and EXCiPACT certifications for its new manufacturing plant.